Objective: To explore care experiences of women who used prescription or illicit opioids and experienced fetal or infant loss.
T he use of prescription and illicit opioids in the United States has increased significantly in the past 10 years (Ailes et al., 2015; Patrick, Kaplan, Passarella, Davis, & Lorch, 2014; Tolia et al., 2015) . This increase has created a public health crisis of increased opioid dependence and addiction, drug overdose, and corresponding infectious disease (Degenhardt & Hall, 2012; C. M. Jones, Mack, & Paulozzi, 2013; Paulozzi, 2006; Roy et al., 2011) . Opioid dependence during pregnancy presents unique perinatal health risks for women and their infants, including intrauterine fetal demise, low birth weight, preterm labor, and fetal and infant loss (Goettler & Tschudin, 2014; Pinto et al., 2010; Whiteman et al., 2014) . Women who use opioids during pregnancy have complex needs, including addiction therapy, behavioral evaluation and treatment, and social support, and these needs are frequently not able to be met through conventional prenatal care approaches (H. E. Jones et al., 2008; Winklbaur et al., 2008) . Although coordinated care is critical for these women, little is known about care needs from the women's perspectives. The purpose of our qualitative study was to explore care experiences of women who used opioids throughout pregnancy and experienced fetal or infant loss.
Literature Review

Needs for Prenatal and Drug Treatment Care
From 2000 to 2009, the prevalence of opioid use in the prenatal period increased fivefold, from 1.2 to 5.6 per 1,000 live births (Patrick, Davis, Lehmann, & Cooper, 2015) . Compared with the general population, women who use opioids have greater rates of preterm birth (25% vs. 9.6%), low birth weight (31% vs. 5% to 8%), and intrauterine growth restriction (30% vs. 8%; Pinto et al., 2010) . In response to the rapid increase in the use and abuse of opioids, the federal government passed the Protecting Our Infants Act of 2015. With this legislation, agencies were directed to develop strategies to prevent and treat opioid use during pregnancy and neonatal abstinence syndrome (NAS) by assessing the comprehensive health care needs of women who use opioids during pregnancy and the long-term consequences of prenatal opioid exposure on infants (Ruble, 2016) . The American College of Obstetricians and Gynecologists (ACOG; 2012) developed policy statements and clinical care recommendations to improve prenatal care, expand substance abuse treatment availability and accessibility, and reduce NAS. Prenatal care for women who use opioids includes assessment of substance use history; referral to tertiary obstetric services or drug treatment specialists; opioid substitution therapy during antenatal, birth, and postpartum stages; and management of relapse (Abrahams, Chase, Desmoulin, Roukema, & Uddin, 2012; Arunogiri, Foo, Frei, & Lubman, 2013; Winklbaur et al., 2008) .
Opioid use remains one of the most common reasons that women do not seek early prenatal care (Friedman, Heneghan, & Rosenthal, 2009; Schempf & Strobino, 2009 ). The stigma attached to the use of drugs during pregnancy could be a barrier. Public discourse and media attention have been focused on the dangers of fetal exposure without taking into account the history of each woman (Kennedy-Hendricks, McGinty, & Barry, 2016) . Also, the complex physical, psychological, and social needs of this population make it difficult to design appropriate, comprehensive, and coordinated care. Women who use opioids during pregnancy are at greater risk for perinatal complications and require high-risk pregnancy services; they have additional needs for substance abuse treatment, chronic pain treatment, behavioral health services, and social support.
Attitudes of care providers toward pregnant women who use opioids may also deter the women from seeking care. Goodman and Wolff (2013) found that 46% to 95% of physicians believed that drug or alcohol use during pregnancy is a form of child abuse and favored compulsory treatment for the women. However, drug treatment, such as opioid substitution therapy, may not always be viewed by women as helpful. Chandler et al. (2013) found that some women perceived opioid substitution therapy as a barrier to normal family life because substitute drugs (e.g., methadone) gave them "a kind of fuzzy feeling" (p. e39), and drug treatment required frequent trips to care centers and disclosure of their drug histories to more people. As suggested by H. E. Jones et al. (2008) , advancement of an evidence-based approach to optimal care for opioid-dependent pregnant women is possible only when we know more about their needs.
Care and Support for Women Who Use Opioids as They Transition to Motherhood
In the Transition Framework developed by Meleis, Sawyer, Im, Messias, and Schumacher (2000) , pregnancy, childbirth, and parenthood are viewed as life transitions. A healthy transition enables an individual to feel connected, better interact with others, and develop confidence and coping strategies. Although many women easily transition to motherhood, women who use opioids may be challenged by difficulties in developing the mother-infant relationship, loss of custody, or death of the infant. Prenatal opioid use was associated with insecurity in attachment to the infant, rehospitalization, and child abuse and neglect (Foulkes, 2015; Friedman et al., 2009; Terplan, Kennedy-Hendricks, & Chisolm, 2015; Worcel, Furrer, Green, Burrus, & Finigan, 2008) . Women who use drugs may be less sensitive to infant cues and may have inadequate infant care knowledge and skills. The removal of an infant from a woman who uses opioids and placement in a different family environment is often done to offer protection to the infant (D. K. Smith, Johnson, Pears, Fisher, & DeGarmo, 2007; Young, Boles, & Otero, 2007) . However, this course of action may be viewed by the woman as punitive and can be detrimental to her recovery and treatment compliance (Krans & Patrick, 2016; Ordean, Kahan, Graves, Abrahams, & Kim, 2015; Stone, 2015; Worcel et al., 2008) . Nevertheless, loss of parental rights or custody is common for women who use drugs and constitutes an involuntary loss, which can cause grief and persistent anger. This could result in the need to blame others to minimize the consequences attributable to substance abuse and allow the woman to manage guilt and maintain her maternal identity (Sykes, 2011; Wells, 2011) .
Another type of loss experienced by women who use opioids is perinatal or infant death. Women who abuse substances are 3 to 4 times more likely to experience fetal or infant death than the general population (King-Hele et al., 2009) . Potential complications of opioid use that increase these risks are intrauterine growth restriction, premature labor, placental abruption, and sudden unexpected infant death (H. E. Whiteman et al., 2014) . Research on the perinatal or infant death experiences of women who use opioids is limited. In some studies, participants described fetal and infant loss or death as a painful and traumatic experience during the transition to motherhood (Gaudet, 2010; Kersting & Wagner, 2012; Rubin, 1985; Rubin & Malkinson, 2001) . Women with such loss experienced numbness, yearning, disorientation, and despair (Badenhorst & Hughes, 2007; Bennett, Litz, Lee, & Maguen, 2005) . Unresolved grief reactions may contribute to initial addiction or relapse of substance abuse, and addiction can also hinder the resolution of the grieving process in subsequent losses (C. S. Smith, 2009 ).
Substance use is a potential complication of the grief experience. Bereaved women with substance use disorders had as much as a twofold increase in the need for hospitalization for substance use than women who did not experience a loss (Zuckoff et al., 2006) . Some women seek to maintain relationships with their deceased children by carrying photographs and observing anniversaries; others may withhold emotional attachment in subsequent pregnancies until the perceived threat of loss is resolved (Lewis, 2006) . Even though rates of perinatal loss are increased with maternal opioid use and the number of women who use opioids during pregnancy is increasing, there is little information in current literature about the unique aspects of these women's experiences. Our study, which was based on Fetal and Infant Mortality Review (FIMR) interviews, was designed to explore the care experiences of women who used prescribed or illicit opioids during pregnancy and had fetal or infant loss.
Methods
Design
We conducted a thematic analysis (Sandelowski, 2000; Vaismoradi, Turunen, & Bondas, 2013) of qualitative maternal interview data from an FIMR program in a Midwestern county department of public health in the United States. Our study was approved by the Institutional Review Board of Indiana University. Only de-identified FIMR data were used and were stored in a passwordprotected drive used specifically for research data.
Participants
To meet our inclusion criteria, participants were required to be 18 years of age or older with known histories of prenatal opioid use and fetal or infant losses. Between the years 2007 and 2012, the local FIMR program reviewed a total of 381 infant mortality cases; 194 (51%) of the mothers participated in interviews. In the same period, 26 adult mothers experienced a fetal or infant loss and were also identified as opioid users (prescribed or illicit). Of those 26 women, 11 (42.3%) participated in a semistructured telephone or in-person interview. Data from the 11 interviews were analyzed in this study. Interviews were conducted between 3.5 and 10 months after the fetal or neonatal death (mean, 5.2 months). Nine participants were interviewed within 5 months of their infants' deaths.
Data Collection
The 11 interviews were conducted by four FIMR program nurses who received the national FIMR maternal interview training on how to conduct an interview, comply with public health and safety codes, and handle difficult encounters. The interview questions that were posed to the participants were focused on their thoughts and perceptions of the care they and their infants received and their experiences throughout the pregnancy and loss (see Table 1 ). Interviewers took detailed written notes during the interviews. No audio or video recordings of the interviews Please tell me about the last few days of your pregnancy, your labor, and when your baby was born.
How satisfied were you with the prenatal care you received?
How was your baby's death explained to you?
What is your understanding of your baby's death?
Share what happened after your baby's death.
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were made because of the sensitive nature of the subject. Interview notes were typed and saved in an FIMR database.
Data Analysis
Coding and thematic analyses were conducted in three phases with the use of the thematic analysis process described by Vaismoradi et al. (2013) . The first author is a neonatal nurse practitioner and a PhD student with experience in treating infants with NAS. The second author is a prenatal health behavior researcher with experience in qualitative data analysis. In the first phase, to familiarize ourselves with the data, we read interview documents several times along with abstracted medical, obstetric, and infant data. The second phase of data analysis consisted of organizing data, including generating initial codes, searching for themes, and reviewing and naming themes. Interview data were initially organized on the basis of the experience of pregnancy, birth, and postpartum periods (including care of the newborn) and infant care (up to 1 year). We coded interviews independently; codes with similar meaning were grouped into themes within each perinatal stage. We then met in person to resolve coding and themenaming discrepancies. Finally, codes and themes were reviewed by two additional authors, a neonatologist with experience in qualitative research and the FIMR process and the coordinator of the local FIMR program. These two team members verified whether they could follow the analysis processes (dependability) and commented on whether the themes in each stage were meaningful to individuals in clinical and public health practices (transferability). Discrepancies in this phase were resolved by group discussion via e-mail. Data saturation was reached in each theme.
Results
Participants
The sample consisted of 11 participants (see Table 2 ). The participants ranged in age from 18 to 36 years. Most were White (n ¼ 8), single (n ¼ 9), and with less than high school education (n ¼ 7). Nine participants used opioids exclusively, and two reported or had positive test results for polysubstance abuse. Five participants used prescription opioids for chronic pain, one participant was in a drug rehabilitation program and used methadone, and five participants used opioids illicitly. Three deaths occurred before birth (intrauterine fetal demise), three occurred during the neonatal period (first month after birth), and the remaining five occurred in infancy (1 month to 1 year after birth). Six deaths were related to prematurity or congenital/genetic abnormalities, and five were caused by sudden unexpected death, pneumonia, placental abruption, or unknown causes.
Themes
Five themes were identified that represented the experiences of participants: Frustration and anger related to not being heard, feeling minimalized; Being overwhelmed with attempts to process and understand medical complications and outcomes; Profound sense of grief and coping with loss; Need to understand why and make difficult decisions; and Placing blame and guilt over death.
Frustration and anger related to not being heard, feeling minimalized. Many participants voiced their frustration that care providers did not listen to their concerns during pregnancy or the infant's illness. They wanted care providers to value their input and experiences. They also wanted care providers to "listen to" and "pay attention to" them: "My baby could have been saved if my prenatal doctor would've listened to me and paid attention to me." "I think if they looked more into what I was going through my loss could have been prevented." "I took her to the clinic multiple times . and the doctors kept saying she was fine and not to worry about it. Then in May, I took her to get her shots and the next thing I know she's dead."
Some participants stated that providers did not ask what they wanted with regard to their infants' care. Some believed that they knew something was wrong, but care providers did not listen to their concerns: "I knew something was wrong. They never listened to me. They were all against me, and never asked what I wanted." "If my prenatal doctor would've listened to me and paid attention to my extremely high blood pressure; took my son . when I begged her to because I had preeclampsia and my son's heartbeat was only 118." Some participants felt "upset" because they were not adequately informed about complications Women who were dependent on opioids and experienced fetal or infant loss had multiple medical and behavioral health issues and often reported that care providers minimized their concerns.
Scott, L. F., Shieh, C., Umoren, R. A., and Conard, T.
and medical treatment. They were not allowed to fully participate in care decisions. If explanations were offered, they did not facilitate the participants' understanding. The lack of information and communication frustrated the participants and contributed to their feelings of being ignored and marginalized in making care decisions:
Everything was going okay, not great, but okay. Then one day they told me that they removed the breathing tube, without my permission. He didn't like it, and they had to put it back in. When they put it back in, they punctured a lung and messed everything up. We had no idea what was going on, and all of sudden they handed me my son and said he was dead. I called the father; he was driving home from work, and I told him I was holding our dead baby. We had no idea what happened. I was so upset. I needed to get out of there.
Being overwhelmed with attempts to process and understand medical complications and outcomes. Some participants had preexisting medical problems (e.g., hypertension, obesity, sexually transmitted infection, hypothyroidism, sickle cell trait) and pregnancy complications, such as vaginal bleeding, placental insufficiency, or chorioamnionitis. Some participants also reported behavioral health issues such as bipolar disorder, anxiety, depression, and schizophrenia. 
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These medical and behavioral comorbidities added complexity to their prenatal care and often required referrals: "I went from jail to the mental hospital, and they put me on a medication called Lurasidone that killed my baby. With my other children, I wasn't taking no medication, and nothing like that happened." "My OB saw me while I was in the hospital and decided to transfer me to another hospital because they didn't know what else to do. I had two blood transfusions, and they stopped the magnesium."
It was sometimes difficult for participants to identify physical signs of complications such as preterm labor. Some were seen and evaluated and sent home. As a result, they did not know whether they were actually in labor when the pain recurred: "I was having pains in my side and didn't realize I was having contractions until I got to the hospital." "I stayed home until the pain became unbearable and then went back to the hospital."
Other complications during pregnancy were also common in the participants. Thoughts about hemorrhage, placental problems, and pregnancy-induced hypertension worried some participants and increased their anxiety levels. They reported that they were anxious about their treatment, being transferred to another hospital, the need for a cesarean birth, and the uncertainty of the newborn's survival: "She was born 2 weeks before that time she could live. Her heart and lungs were underdeveloped. They said she might make it and might not." "I went to the hospital and was bleeding everywhere. Pool of blood. They said my daughter swallowed it."
Profound sense of grief and coping with loss. Participants struggled to deal with grief. They expressed "how lost I feel about losing him," and "this is a very hard thing to go through." Some participants wished "there was something you can do" to bring back their infants. Others were grateful to have other children who were alive: "Do you know how hard it is to deal with this after having him inside you all these months and then touching his hands and feet? This has been the worst 5 months of my life." "That is a very hard thing to go through, and you still wish there was something you could do." ". just how lost I feel about losing him and how lost I am without him! I just thank God for my other sons."
Participants talked about the support they received during their experiences with grief. Some participants had difficulty managing their grief, and others actively made plans for closure through memorial services for their infants, spirituality, and family support. They sought validation for their feelings of grief and loss but sometimes felt pushed by family and friends to move on: "We had a memorial service for him and buried him at the cemetery.. We are doing okay with the loss; we have a lot of family." "Can I ask you something? People tell me the more I talk about her, or keep wanting to celebrate her birthday, I will never get over her.. Do you think it is okay to celebrate her birthday?"
Need to understand why and make difficult decisions. Participants expressed that they were adept at recognizing changes in their infants' health statuses (e.g., coughing and throwing up or not breathing), particularly after hospital discharge. They sought medical attention and explanations. However, there were times some participants had to make difficult decisions about care and treatment: "My baby did good at first. When he was three and a half or four months old, I noticed he couldn't open his hand or sit up straight." "I took her to the hospital and clinic multiple times because she was coughing and throwing up." "I called out for someone to call 911 and started CPR, but it was already too late." "His father and I decided to take him off the machine."
Participants wanted to understand and make sense of their infants' deaths. Knowing how and why their infants died appeared to offer them "closure." Knowing the cause of infant death was Scott, L. F., Shieh, C., Umoren, R. A., and Conard, T.
also important for them to understand implications for future children. They also wanted reassurance that their care as parents and the health care provided were sufficient because "they did what they could" for their infants: "Well, at least now we have closure. I wish someone had told us sooner; we have been going nuts not knowing." "Now I know he did die because of sleep apnea." "They said she had a tube defect and it was an encephalocele, and she couldn't live." "I don't remember the name of the condition he had, but the doctors said it was genetic."
Placing blame and guilt over death. Participants responded to infant death with two reactions. Some participants blamed health care providers because "they are responsible for" their infants' deaths. Others blamed themselves for their infants' deaths and believed that if they had done something to help their infants, then the deaths would not have occurred: "I believe the OB doctors should be checked out. My baby could have been saved.." "I wanted to sue the hospital and clinic because they are responsible for her death."
At times, pressure from family and friends precipitated feelings of self-blame and guilt. Occasionally, participants blamed themselves and searched for how they might have prevented the death: "If we had used the monitor, he might be alive. I wish we had kept on using the machine anyway." "All my friends and family thought I killed my baby. They kept saying I smothered her and stuff. My mom was real angry, but she was also crying."
When I woke up, I knew something was wrong. I freaked out. So I told everyone she died in her crib. But she was in bed with me. I tell everyone I know, see with a baby, everyone, not to sleep with their baby.
Discussion
Our results indicate that women who used opioids and experienced infant or fetal loss had complex needs, which were often unmet. Of note, participants in our study repeatedly voiced concerns about not being heard and about being ignored and undervalued. These concerns may be related to the stigma of addiction; however, it is also likely that they may have been exacerbated by participants' anxiety about their high-risk conditions and frequent urgent medical treatments. The perception that their feelings were minimalized could also reflect their frustration and helplessness with regard to the deaths of their infants. In previous studies on addiction, women expressed feelings of stigmatization from family, friends, society, and health care providers (Chandler et al., 2013; Earnshaw, Smith, & Copenhaver, 2013; McGinty, Goldman, Pescosolido, & Barry, 2015) . If allowed to develop, these perceptions of stigma can create a lack of trust in individual health care providers and the health care system and serve as barriers to accessing care (Casper & Arbour, 2013; Winklbaur et al., 2008) .
Many participants in our study had difficulty understanding why devastating medical complications occurred for them and their infants and often believed that the communication from health care providers was inadequate, incomplete, or difficult to understand. This problem of incomplete understanding may be caused partially by the stress and uncertainty of the situation itself but also may reflect a lack of communication skills among health care providers (Pozzo, Brusati, & Cetin, 2010) . Results of several previous studies conducted with patient populations who faced high-stress and complex medical situations, such as cancer or high-risk pregnancy, indicated the need for providers to follow standard protocols and to have practice in delivering bad news (Pozzo et al., 2010) . In the context of opioid users who experience fetal and infant complications, providers could also be helped in their regular communications with additional training on how to deal with a woman's emotional reaction and her need to be well informed. Communication would be enhanced if health care providers created illustrations and provided information in clear and simple terms. Women who reported satisfaction with the information they received were better prepared to take action and make good decisions (Makary, 2015) .
Dealing with grief, guilt, and blame was an ongoing process for participants from the first time infant complications were identified and continuing through their infants' deaths and the months that followed. Although every woman grieves in her own way, lack of support may prolong grief (Badenhorst & Hughes, 2007; Cacciatore, Schnebly, & Froen, 2009; Kersting & Wagner, 2012) . Moreover, the perinatal loss can be a trigger for addiction relapse (C. S. Smith, 2009) . Bereavement support can help women with fetal or infant loss acknowledge their feelings of guilt over blame and the added burden of Care for Women Who Use Opioids and Experience Fetal/Infant Loss stigmatizing addiction (Bennett et al., 2005; Murphy, Shevlin, & Elklit, 2014) .
Anger and blame toward others or self is a typical reaction after a perinatal loss, particularly when mothers feel unsupported or uninformed (Badenhorst & Hughes, 2007; Cacciatore, Frøen, & Killian, 2013; McCreight, 2008) . Providers must recognize that grief may be expressed in many ways, including blaming others. Blame is a normal aspect of grief in perinatal loss; many mothers blame themselves for their losses, and such blame may act as a barrier to the resolution of grief (Cacciatore et al., 2013) . However, our participants turned blame toward themselves with less frequency than in general perinatal grief studies (Badenhorst & Hughes, 2007; Kersting & Wagner, 2012) . The extension of blame to others may represent an abnormal grief reaction related to the need to minimize implications of substance use. Regardless of the reason, support and counseling are essential.
Limitations
The use of secondary data analysis provided only a narrow window into the care experiences of the participants. The FIMR interview was constructed for the specific purpose of identifying multiple maternal and infant health care, social, and community service issues. We were unable to clarify participants' care experiences with additional interview questions. We were also unable to explore specific care experiences regarding methadone use or other drug treatment during pregnancy. The interviews were not recorded as audio or visual media. Although extensive written notes were completed on the basis of the FIMR protocols, written notes might not have captured all information given by each participant during the interview. The range of time between the loss and the interview (3.5 to 10 months) is also a possible limitation. Grief is an individual experience, and women interviewed soon after their infants' deaths may report experiences that are very different from those of women interviewed several months later. Unique perspectives related to opioid use and dependence may also affect the grief experience.
The use of secondary data analysis also prevented us from conducting member checks to review the themes identified with the participants, which would have helped validate our findings. Our study was limited to a small number of women in one local FIMR program. Additional research is needed to determine whether our findings are similar to those from other women with opioid use who experience fetal or neonatal loss.
Implications for Practice
Our findings indicate that health care providers must partner with women who use opioids to design care approaches and make treatment decisions that acknowledge their needs, perceptions, and satisfaction (Wolf, Lehman, Quinlin, Zullo, & Hoffman, 2008) . Engagement in such a partnership fosters respect, shared decisionmaking practices, and a caring environment in which the concerns of women who use opioids can be addressed. With a partnership focus, care providers may be more sensitive to the needs of these women to help reduce the perception of stigmatization and increase the perception of being valued.
The need for health care provider education and training in effective and sensitive communication is evident from this study. Participants believed that caregivers did not listen to them, minimized their feelings, and were unsupportive, all of which contributed to their pain, guilt, and bereavement. Health care providers must project acceptance, accessibility, and readiness to listen and offer understandable medical information about the care provided and procedures performed (Fleischer, Berg, Zimmermann, Wüste, & Behrens, 2009) . Communication must be bidirectional, and a woman's interpretation of a message may be very different from what a nurse or another provider intended (Kourkouta & Papathanasiou, 2014) . It is also necessary to continually assess a woman's knowledge and confirm her understanding of the health information given.
Comprehensive multidisciplinary care models may provide opportunities for care providers from different disciplines to develop coordinated care plans for women who use opioids and their infants, as well as to enhance communication among care providers. In continuing education programs or at conferences, multidisciplinary aspects of care for women who use opioids could be emphasized.
Bereavement support and counseling is particularly important for women who use opioids and Interdisciplinary care, skillful communication, and patientcentered care are needed for women with histories of opioid use who experience fetal or infant loss.
experience perinatal or infant death. Long-term provision of such support and counseling may be needed to resolve a woman's reactions of guilt, anger, and blame. To improve patientprovider communication and address individual and system failures, which may lead to poor outcomes, formal review processes such as FIMR and Child Death Review programs may be helpful.
Recommendations for Future Research
Further exploration of this topic could best be accomplished with a phenomenology approach that uses open-ended interviews. This would provide a richer and more complete description of the participants' experiences. More focused exploration divided by the time frame of the loss (fetal, neonatal, or infant) may also aid in theory development, as well as further defined guidelines for effective practice.
Conclusions
The rapid increase in the prevalence of opioid use among pregnant women has led federal agencies to demand more research to determine the best practices for these women and their infants. We examined the care experiences of women who used opioids throughout pregnancy and experienced fetal or infant loss. The five themes identified in this study indicate a need for interdisciplinary team care, partnership in decisions, provider training for skillful communication, and emotional support for women with opioid use and pregnancy or infant loss.
